Fluridil
aka - Eucapil
- Topilutamide
- BP-766
Fluridil is a nonsteroidal anti-androgen (NSAA) specifically designed for topical use in the treatment of androgenetic alopecia in both men and women. It is closely related to other NSAAs such as flutamide and bicalutamide.
Introduced for medical use in 2003 and currently available in Europe, particularly in the Czech Republic and Slovakia, Fluridil works by targeting androgen receptors in the hair follicles without systemic absorption, thereby preventing the hormone-induced follicle miniaturization characteristic of AGA. Unlike other hair loss treatments, Fluridil's unique chemistry allows it to rapidly degrade in the presence of water, minimizing potential systemic side effects.
Research on Fluridil for treating androgenetic alopecia (AGA) underscores its efficacy and safety as a topical anti-androgen. Studies have demonstrated Fluridil's capacity to safely enhance hair growth in men with AGA by increasing the anagen to telogen ratio, a beneficial effect that begins within the first three months of use and can persist for up to nine months. Developed to suppress the androgen receptor specifically in the scalp, Fluridil is designed for rapid degradation to prevent systemic side effects, making it a unique candidate for those seeking a targeted approach to hair loss treatment without the systemic side effects associated with oral medications.
Community sentiment towards Eucapil is mixed, with many users reporting a decrease in hair loss and some improvement in hair density, usually after consistent use for several months. It is generally considered safe, with reported side effects being mild and mostly limited to scalp irritation due to the solvent isopropyl alcohol.
Fluridil presents a promising option for individuals seeking a topical solution to AGA with minimal systemic side effects, it's important to consult with a healthcare professional before starting any new treatment. The unique properties of Fluridil, including its rapid degradation and targeted action, make it a noteworthy consideration in the array of hair loss treatments available. However, further research and broader availability could help solidify its position and efficacy in the hair loss treatment landscape.
Research
20 / 46 results
research Fluridil, A Rationally Designed Topical Agent For Androgenetic Alopecia: First Clinical Experience
research Development of Fluridil, a Topical Suppressor of the Androgen Receptor in Androgenetic Alopecia
research Fluridil, a Rationally Designed Topical Agent for Androgenetic Alopecia
research Investigational Medications in the Treatment of Alopecia
research Addressing Androgenetic Alopecia: A Complex Disorder with a Multilateral Treatment Strategy
research Medications and Hair Transplantation
research Pathobiology of Androgenetic Alopecia
research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men
research Androgenetic Alopecia: An Evidence-Based Treatment Update
research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men – Short Version
research Drug Discovery for Alopecia: Gone Today, Hair Tomorrow
research Pattern Hair Loss in Men: Diagnosis, Genetic Link, Clinical Features, and Treatments
research Multi-Therapies in Androgenetic Alopecia: Review and Clinical Experiences
research What Does Androgenetic Alopecia Have to Do with COVID-19? An Insight into a Potential New Therapy
research Hair: What Is New in Diagnosis and Management?
research Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism
research Female Androgenetic Alopecia: An Update on Diagnosis and Management
research Skin Academy: Hair, Skin, Hormones and Menopause – Current Status on the Management of Hair Disorders in Menopausal Women
research An Overview of Herbal Alternatives in Androgenetic Alopecia
